
CNTN · NASDAQ
Canton Strategic Holdings Inc
$2.15 +0.20 (+10.26%)
Company overview
Canton Strategic Holdings, Inc. focuses on leveraging Canton Coin and supporting the Canton network to advance institutional blockchain adoption and the digitization of financial markets. The company is also involved in research and development of GV104, a buccal film technology that has completed a Phase 1 trial for respiratory and/or nervous system depression in military personnel and chemical incident responders, as well as GV023, an oral formulation of infliximab that addresses a critical limitation of the IV gold standard by eliminating the treatment burden of repeated intravenous infusions. The company was formerly known as Tharimmune, Inc. and changed its name to Canton Strategic Holdings, Inc. in February 2026. Canton Strategic Holdings, Inc. was founded in 2017 and is based in Red Bank, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $171M
- Employees
- 2
- Headquarters
- Red Bank, NJ
- Website
- cantonstrategic.com
- CEO
- Mark Wendland
- Listed
- March 28, 2024
- P/E
- -5.97
- Dividend yield
- 0.00%
Company financials
- Revenue
- $0.00
- Gross profit
- $0.00
- Operating income
- -$54.4M
- EBITDA
- -$64.9M
- Net income
- -$80.7M
- EPS
- -$0.36
- Total assets
- $585M
- Total debt
- $0.00
- Earnings yield
- -16.74%
No annual segmentation.
No geographic segmentation.
News